iNSC-TRAIL

iNSC-TRAIL is an experimental cell-based therapeutic consisting of human induced neural stem cells (iNSCs) genetically engineered to express tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Developed primarily at the University of North Carolina at Chapel Hill, this platform leverages the innate tumor-homing capabilities of neural stem cells to deliver the pro-apoptotic protein TRAIL directly to glioblastoma (GBM) foci. The iNSCs are typically derived from fibroblasts through direct reprogramming. Once at the tumor site, the secreted TRAIL binds to death receptors on the surface of cancer cells, selectively triggering apoptosis while sparing healthy brain tissue. To enhance therapeutic durability and persistence within the tumor resection cavity, the cells are often encapsulated in a biocompatible scaffold matrix, such as a gelatin-thrombin or fibrin-based hydrogel. Preclinical studies have demonstrated that iNSC-TRAIL can significantly increase survival and reduce tumor burden in various GBM models, including those capturing intratumoral heterogeneity.

Other names

induced neural stem cells expressing TRAILtNSC-TRAILtumoricidal neural stem cell therapy